Results 71 to 80 of about 25,289 (245)

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Spectrophotometric Investigation of Metal Complexes with Valsartan [PDF]

, 2018
To develop a simple, accurate, precision and economical UV-Vis spectrophotometric and mole ratio method for the analysis in pharmaceutical formulations by making its complexes with calcium(II) and magnesium(II). In this study, the separately spectrums of
KARADERI, Serap, MAZI, Caner, ARIOZ, Filiz   +2 more
core   +1 more source

Effect of sacubitril/valsartan on lipid metabolism in patients with chronic kidney disease combined with chronic heart failure: a retrospective study

Lipids in Health and Disease
Background and objective Dyslipidemia is significantly more common in those with concurrent chronic kidney disease (CKD) and chronic heart failure (CHF).
Manzhi Li, Ao Zhong, Yifan Tang, Jinnuo Yu, Mengmeng Wu, Karthick Kumaran Munisamy Selvam, Dong Sun   +6 more
doaj   +1 more source

Valsartan ameliorated cognitive decline, oxidative stress and inflammation in AlCl3-induced Alzheimer's disease in rats [PDF]

ERU Research Journal
Alzheimer's disease (AD) is a chronic neurodegenerative disease that results in cognitive and memory deficits. The objective of the study was to investigate the potential neuroprotective effects of valsartan against the neurobehavioral and pathological ...
Noha Saeed, Manar Esmail, Hanaa Abdel-Rahman, Ali Elgindy   +3 more
doaj   +1 more source

Valsartan in the treatment of heart attack survivors

, 2006
Bodh I JugduttDivision of Cardiology, Department of Medicine, University of Alberta, Edmonton, Alberta, CanadaAbstract: Survivors of myocardial infarction (MI) are at high risk of disability and death. This is due to infarct-related complications such as
Bodh I Jugdutt
core  

Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria [PDF]

, 2006
Cilnidipine, an L-/N-type calcium channel blocker, dilates the efferent glomerular arterioles in an experimental model and shows a renoprotective effect, but its clinical benefits and safety have not yet been assessed in type II diabetics with ...
H. Ishikawa, T. Nakano, Koyabu, S., Nakano, T., Ishikawa, H., T. Murata, Katayama, K., S. Koyabu, K. Katayama, S. Nomura, Nomura, S., Murata, T.   +11 more
core   +1 more source

Association of BMI with adherence and outcome in heart failure patients treated with wearable cardioverter defibrillator

ESC Heart Failure, Volume 12, Issue 2, Page 1295-1303, April 2025.
Abstract Background Obesity is a known risk factor for cardiovascular disease (CVD), yet an ‘obesity paradox’ has been observed in various CVD contexts. The impact of obesity on heart failure (HF) patients treated with a wearable cardioverter‐defibrillator (WCD) remains underexplored.
Mohammad Abumayyaleh, Katharina Koepsel, Julia W. Erath, Thomas Kuntz, Norbert Klein, Boldizsar Kovacs, Firat Duru, Ardan M. Saguner, Christian Blockhaus, Dong‐In Shin, Fabienne Kreimer, Michael Gotzmann, Hendrik Lapp, Thomas Beiert, Assem Aweimer, Andreas Mügge, Christel Weiß, Ibrahim El‐Battrawy, Ibrahim Akin   +18 more
wiley   +1 more source

Overview of clinical use and side effect profile of valsartan in Chinese hypertensive patients

, 2013
Qi-Fang Huang, Yan Li, Ji-Guang WangCentre for Epidemiological Studies and Clinical Trials, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People's Republic of ChinaAbstract: We ...
Li Y, Huang QF, Wang JG
core  

Sacubitril/valsartan preserves regional cardiac function following myocardial infarction in rats

ESC Heart Failure, Volume 12, Issue 2, Page 1304-1315, April 2025.
Parts of the figure were drawn by using pictures from Servier Medical Art. Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License (https://creativecommons.org/licenses/by/3.0/). Abstract Aims Sacubitril/valsartan (Sac/Val) is used for treatment of heart failure. The effect of Sac/Val on regional dysfunction
Einar Sjaastad Nordén, Bård Andre Bendiksen, Kaja Knudsen Bergo, Emil Knut Stenersen Espe, Gary McGinley, Almira Hasic, Ida Marie Hauge‐Iversen, Hege Katrin Ugland, Xin Shen, Michael Frisk, Nishani S. Mabotuwana, William E. Louch, Rizwan I. Hussain, Lili Zhang, Ivar Sjaastad, Alessandro Cataliotti, Geir Christensen   +16 more
wiley   +1 more source

Variability in Response to Valsartan and Its Relationship With AGT M235T Genotype and Other Nongenetic Parameters Among a Sample of Hypertensive Individuals in Jordan: A Prospective Pilot Study

Health Science Reports
Background Valsartan, an angiotensin receptor antagonist widely used in hypertension and heart failure management, exhibits noticeable interindividual variation in response among hypertensive patients at the University of Jordan Hospital.
Hussein Alhawari, Yazun Jarrar, Malek Zihlif, Ayman Wahbeh, Sameeha Alshelleh, Khaled Ojjoh, Dalia Abdelrazaq, Hussam Alhawari   +7 more
doaj   +1 more source